Carl Reynolds, MD
Cardiovascular Disease · Philadelphia, PANPI 1770502221
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,197 of the $2,596 with a category attached, or 84.6%. Abbott accounts for 91.5% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $1,603, more than ten times the $17 reported in 2019.
Across 18 payments — averaging $144.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$127
- Boston Scientific$38
- Impulse Dynamics (USA) Inc.$35
- GE HealthCare$20
What the payments were for
- Travel & lodging$2,19785%
- Food & beverage$39915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $2,375 |
| Abiomed | 1 | $127 |
| Boston Scientific | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 1 | $35 |
| GE HealthCare | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,596 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndaqelTafamidis Meglumine | 12 | $249,228 |
| EliquisApixaban | 166 | $190,172 |
| XareltoRivaroxaban | 86 | $106,481 |
| EntrestoSacubitril/Valsartan | 74 | $67,751 |
| JardianceEmpagliflozin | 34 | $41,494 |
| FarxigaDapagliflozin Propanediol | 25 | $35,458 |
| Repatha SureclickEvolocumab | 35 | $26,566 |
| MultaqDronedarone Hcl | 14 | $20,314 |
| WegovySemaglutide | 12 | $15,364 |
| OzempicSemaglutide | 15 | $13,783 |
| Praluent PenAlirocumab | 21 | $10,807 |
| Rosuvastatin Calcium | 186 | $4,640 |
| Metoprolol Succinate | 260 | $3,829 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 30 | $3,394 |
| Olmesartan Medoxomil | 119 | $3,359 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.